Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 1,100 Shares of Insulet Corporation $PODD

Key Points

• The Fjarde AP Fonden Fourth Swedish National Pension Fund has reduced its stake in Insulet Corporation by 9.7%, now owning 10,200 shares valued at approximately $2.68 million.
• Insulet reported a quarterly earnings per share of $1.17, exceeding estimates, and achieved revenue of $649.10 million, representing a 32.9% increase from the previous year.
• Multiple analysts have given Insulet a "buy" rating, with target prices ranging from $350.00 to $380.00, highlighting positive sentiment toward the stock's performance.

Fjarde AP Fonden Fourth Swedish National Pension Fund lessened its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 9.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,200 shares of the medical instruments supplier's stock after selling 1,100 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in Insulet were worth $2,679,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. OLD National Bancorp IN grew its position in shares of Insulet by 6.7% in the 1st quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier's stock valued at $231,000 after buying an additional 55 shares during the last quarter. Cooper Financial Group lifted its stake in shares of Insulet by 5.7% in the first quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier's stock worth $283,000 after acquiring an additional 58 shares during the period. Syon Capital LLC boosted its holdings in Insulet by 5.6% in the fourth quarter. Syon Capital LLC now owns 1,114 shares of the medical instruments supplier's stock valued at $291,000 after acquiring an additional 59 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its position in Insulet by 23.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock valued at $82,000 after purchasing an additional 59 shares during the period. Finally, HighTower Advisors LLC increased its position in Insulet by 2.1% during the 1st quarter. HighTower Advisors LLC now owns 2,882 shares of the medical instruments supplier's stock valued at $757,000 after purchasing an additional 60 shares during the period.

Insulet Stock Down 1.5%

Shares of NASDAQ:PODD traded down $5.0550 during midday trading on Thursday, hitting $327.9450. 307,969 shares of the company's stock were exchanged, compared to its average volume of 766,068. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet Corporation has a 12 month low of $180.31 and a 12 month high of $334.18. The company has a market cap of $23.08 billion, a PE ratio of 100.01, a price-to-earnings-growth ratio of 2.74 and a beta of 1.35. The stock has a 50 day moving average price of $299.94 and a 200-day moving average price of $285.21.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company's revenue for the quarter was up 32.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, sell-side analysts anticipate that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PODD. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Sanford C. Bernstein restated an "outperform" rating on shares of Insulet in a report on Friday, May 16th. Oppenheimer upped their price target on shares of Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Truist Financial started coverage on Insulet in a research report on Monday, June 16th. They issued a "buy" rating and a $365.00 price objective for the company. Finally, Barclays upped their target price on Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research report on Thursday. Sixteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $332.71.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.